文献速递系统性红斑狼疮

如何定义系统性红斑狼疮的低疾病活动度?

How can we define low disease activity in systemic lupus erythematosus?
PubMed 文献 · Semin Arthritis Rheum · 2018-10-16

该综述检索PubMed至2018年7月,汇总SLE低疾病活动度的三种定义(MDA、LDA、LLDAS),明确各自SLEDAI-2K阈值、用药限制及血清学纳入差异,指出三者均与长期损伤累积减少和死亡率降低相关,可作为治疗目标和临床试验终点,但尚需共识统一。

要点

  • MDA要求临床SLEDAI-2K≤1,允许抗疟药、标准剂量免疫抑制剂及泼尼松≤5 mg/天。
  • LDA要求临床SLEDAI-2K≤2,仅允许抗疟药维持;LLDAS要求SLEDAI-2K≤4且无主要器官活动。
  • 三种低疾病活动度定义均与长期损伤累积减少和死亡率降低相关,但血清学纳入标准不一致。

核心结论

  • 有充分证据表明SLE低疾病活动度与长期结局改善相关,可作为日常实践和临床试验的治疗目标,未来需推进统一定义的共识。

研究设计与样本

  • 综述检索PubMed数据库自建库至2018年7月,检索词包括「lupus」AND「low disease activity」OR「minimal disease activity」。

主要发现

  • 已提出三种SLE低疾病活动度定义:MDA、LDA和LLDAS。
  • MDA定义为临床SLEDAI-2K≤1,使用抗疟药、标准剂量免疫抑制剂和泼尼松≤5 mg/天。
  • LDA允许临床SLEDAI-2K≤2,仅用抗疟药维持。
  • LLDAS接受SLEDAI-2K≤4且无主要器官系统活动,医生整体评估≤1且无新发活动,泼尼松≤7.5 mg/天,使用标准剂量抗疟药、免疫抑制剂和生物制剂。
  • 活动性血清学(抗dsDNA和补体C3/C4)不纳入MDA和LDA,但在LLDAS定义中计入疾病活动。

关键数值与推荐

  • MDA:临床SLEDAI-2K≤1,泼尼松≤5 mg/天,允许抗疟药和标准剂量免疫抑制剂。
  • LDA:临床SLEDAI-2K≤2,仅允许抗疟药维持。
  • LLDAS:SLEDAI-2K≤4且无主要器官系统活动,医生整体评估≤1且无新发活动,泼尼松≤7.5 mg/天,允许标准剂量抗疟药、免疫抑制剂和生物制剂。

临床怎么用

  • 临床可将低疾病活动度作为SLE治疗目标,依据所选定义评估SLEDAI-2K、用药剂量及血清学状态。

局限性

  • 三种定义在血清学纳入和用药限制上存在差异,尚未形成统一共识。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In recent years, low disease activity emerged as a state that is associated with improved long-term outcomes in systemic lupus erythematosus (SLE). Our aim was to review the current concepts for low disease activity in SLE in order to serve as the basis of a future consensus for standardization. METHODS: The PubMed database was searched for relevant articles from inception up to July 2018. Medical Subject Headings (MeSH terms) included "lupus" AND "low disease activity" OR "minimal disease activity". RESULTS: Three different definitions of low disease activity in lupus have been proposed. Minimal disease activity (MDA) is defined as a clinical SLE Disease Activity Index 2000 (SLEDAI-2K)≤1 on antimalarials, immunosuppressives in standard doses and prednisone ≤5 mg/day. Low disease activity (LDA) allows for a clinical SLEDAI-2K≤2 maintained on antimalarials only. Lupus Low Disease Activity State (LLDAS) accepts a SLEDAI-2K≤4 with no activity from major organ systems, a Physician's Global Assessment of ≤1 with no new activity, prednisone dose ≤7.5 mg/day and standard doses of antimalarials, immunosuppressives and biologics. Active serology (anti-dsDNA and complement C3/C4) is not included in the MDA and LDA but counts towards disease activity in the LLDAS definition. All definitions were associated with less damage-accrual and mortality in the long-term that were comparable to those of clinical remission. CONCLUSIONS: There is solid evidence that low disease activity is associated with improved outcomes in SLE and could serve as a therapeutic target in daily practice and clinical trials. Future research should focus on advancing a consensus for the best possible definition.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Tselios K, Gladman DD, Urowitz MB, et al. How can we define low disease activity in systemic lupus erythematosus? Semin Arthritis Rheum. 2018. PMID: 30415943. doi:10.1016/j.semarthrit.2018.10.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。